One of the most exciting advances in the treatment of metastatic non-small-cell lung cancer (NSCLC) is the development of ...

This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical ...

The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that ...

This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment ...

Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic ...

Research shows that TIL therapy, an emerging type of immunotherapy, works in some patients with non-small cell lung cancer, ...

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD ...

Jacobio Pharma is making a play for the Chinese KRAS market, unveiling registrational lung cancer data that suggest its asset ...

Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose ... T cells capable of targeting metastatic sites beyond the injected ...

Non-small cell lung cancer accounts for nearly 85% ... anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results ...

It was also highly accurate in predicting those patients who do not develop metastatic ... Genetic Signature May Predict Response to Immunotherapy for Non-Small Cell Lung Cancer Feb. 23 ...